[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"patient-controlled-intravenous-analgesia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:patient-controlled-intravenous-analgesia":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100633384","phase-4-anrikefon-based-patient-controlled-intravenous-analgesia-following-laparoscopic-surgery-100633384",false,"NCT07525986","Anrikefon-based Patient-controlled Intravenous Analgesia Following Laparoscopic Surgery","Efficacy of Anrikefon-based Patient-controlled Intravenous Analgesia for Pain Management After Laparoscopic Surgery: a Randomized, Double-blind, Active-controlled Pilot Tria","Inclusion Criteria:\n\n1. Aged \\>= 18 years but \\\u003C 75 years;\n2. Scheduled to undergo elective laparoscopic colorectal surgery with an expected duration of \\>=1 hour;\n3. The incisional pain can be covered by the transversus abdominis plane block or rectus sheath block; yet patients still require postoperative patient-controlled intravenous analgesia.\n\nExclusion Criteria:\n\n1. Presence of preoperative cognitive impairment (Mini-Mental State Examination \\[MMSE\\] score \\\u003C 27), or inability to communicate due to language barrier;\n2. Body mass index (BMI) \\> 30 kg\u002Fm² or \\\u003C 18 kg\u002Fm²;\n3. Presence of poorly controlled or untreated comorbidities, including but not limited to the following: hypertension characterized by a resting systolic blood pressure (SBP) \\> 180 mmHg and\u002For diastolic blood pressure (DBP) \\> 110 mmHg, coronary artery disease with unstable angina or myocardial infarction within 6 months, heart failure rated as New York Heart Association classification \\>= III, severe chronic obstructive pulmonary disease (or in a state of acute exacerbation), severe hepatic insufficiency (Child-Pugh grade C), severe renal insufficiency (estimated glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73m²), or American Society of Anesthesiologists (ASA) physical status classification \\>= IV;\n4. Continuous use of opioid analgesics for more than 10 days for any reason, or alcohol abuse (average daily intake of pure alcohol \\> 36 g) within 3 months before screening;\n5. Preoperative use of opioid or non-opioid analgesics with the interval between the last administration and randomization shorter than five half-lives of the drug or the duration of drug action (whichever is longer);\n6. Known allergies or contraindications to opiates or other medications that may be used in this study, such as anesthetics, antiemetics, and nonsteroidal anti-inflammatory drugs (NSAIDs);\n7. Anticipated need for postoperative mechanical ventilation；\n8. Other conditions that are considered unsuitable for study participation.","ALL","18 Years","75 Years",{"count":20,"type":21},140,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Visceral pain following laparoscopic surgery is frequently underestimated, yet it is associated with a range of adverse outcomes. Effective visceral pain management should constitute an essential component of postoperative analgesic strategies following laparoscopic procedures. However, conventional analgesic agents, including μ-opioid receptor agonists, lack specificity for visceral pain. Anrikefon, a novel selective peripheral κ-opioid receptor agonist, demonstrates unique efficacy in alleviating visceral pain with a favorable safety profile. Preliminary studies showed that a single intravenous dose of anrikefon effectively alleviates postoperative pain after abdominal surgery with a low risk of adverse effects. The investigators hypothesize that an appropriate dosing regimen of anrikefon administered via patient-controlled intravenous analgesia (PCIA) pump, as part of a multimodal analgesic strategy, can specifically target and alleviate visceral pain after laparoscopic surgery, thereby achieving comprehensive postoperative analgesia.",[27,28,29,30],"Laparoscopic Surgery","Visceral Pain, Postoperative","Anrikefon","Patient-controlled Intravenous Analgesia",[32,33,29,34],"Laparoscopic surgery","Visceral pain, Postoperative","Patient-controlled intravenous analgesia","RECRUITING","2026-04-22",{"date":38,"type":39},"2026-04-24","ACTUAL",{"date":41,"type":39},"2026-04-14",{"date":43,"type":21},"2027-04",{"name":45,"class":46},"Peking University First Hospital","OTHER"]